Crispr Therapeutics shares tumble after significant earnings miss
Director Jack Levine of Strawberry Fields REIT, Inc. (EXCHANGE:STRW), a $569 million market cap healthcare REIT with a 5.45% dividend yield, recently purchased 10,000 shares of common stock at $9.92, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the purchase was $99,200. The company, which has shown impressive revenue growth of 22% in the last twelve months, appears undervalued according to InvestingPro analysis.
Following the transaction on July 8, 2025, Levine directly owns 130,000 shares through Cameo Life Sciences Investment, LLC. InvestingPro analysis shows the company trading at attractive valuation multiples, with 8 additional exclusive insights available to subscribers. Check out the Most Undervalued Stocks list for more opportunities like STRW.
In other recent news, Strawberry Fields REIT, Inc. raised approximately $87.6 million through a Series B bond offering in Israel. The bonds are trading on the Tel Aviv Stock Exchange, with interest set at an annual rate of 6.70%. The company plans to use the proceeds for ongoing operations and general corporate purposes, including debt repayment and property acquisitions. Additionally, Strawberry Fields REIT expanded its At Market Issuance Sales Agreement to $50 million in common stock shares. This amendment includes the addition of Wedbush Securities Inc. to its existing agreement with B. Riley Securities, Inc. and A.G.P./Alliance Global Partners (NYSE:GLP). The company filed a Prospectus Supplement No. 1 with the SEC to align with the expanded offering. These developments are part of the company’s strategy to strengthen its financial position by leveraging market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.